Gene Logic to Lay Off 80 as Part of Genomics Division Restructuring
Gene Logic said this week that it will lay off approximately 80 employees in its genomics division by Oct. 5 as it restructures the unit.
The company warned of the restructuring in June when it said the genomics division revenues would be "significantly lower" than anticipated for both the second quarter and the full year of 2006. Gene Logic withdrew its financial guidance for 2006 and 2007 as a result.
This week, Gene Logic said the staff reductions will cut its annual salary and fringe benefits costs by approximately $8 million. The company said it also expects “additional savings in certain non-employee costs.”
Following the lay-offs, retained employees will “support existing products and services and ensure ongoing service levels are effectively maintained for current and prospective customers," Gene Logic said.
The company added that “affected employees will be given severance and outplacement assistance costing approximately $1.5 million.”
The lay-offs will not affect Gene Logic's preclinical and drug-repositioning divisions, the company said.
Arup Laboratories to Use SmartGene’s Web-Based Bioinformatics Services
Arup Laboratories, a clinical and anatomic pathology reference laboratory, has subscribed to SmartGene's web-based services for managing, analyzing, and interpreting genetic sequences, the companies said this week.
Arup is the first clinical reference laboratory in North America to use SmartGene’s technology, the company said.
SmartGene, based in Zug, Switzerland, offers the Integrated Database Network System (IDNS), a web-based suite tool for sequence-based molecular identification and typing for a variety of clinical, medical research and veterinary applications.
Financial terms of the agreement were not disclosed.
Cold Spring Biotech To Distribute Partek Software in Taiwan
Partek said this week that Cold Spring Biotech will distribute its software in Taiwan.
Under the terms of the agreement, Cold Spring Biotech will provide sales and support for the Partek Genomics Suite for microarray data, Partek Discovery Suite for multi-dimensional non-microarray data, Partek QSAR Solution for chemistry data, and Partek Screener’s Solution for high-throughput screening data.
Bruker Licenses Health Discovery’s SVM Tech for ClinProTools
Health Discovery said this week that Bruker Daltonics has licensed HDC’s support vector machine technology for use in its ClinProTools clinical proteomics software.
The agreement provides for an up-front fee and royalties based on sales. Financial terms were not disclosed.
Michael Schubert, executive vice president of Bruker Daltonics, said that the SVM technology will complement Bruker’s other classification algorithms, including its Supervised Neural Network and QuickClassifier modified genetic algorithms.
HDC holds a large patent portfolio protecting the use of support vector machines in bioinformatics applications. Last month, the firm sued Ciphergen and Equbits for patent infringement.
GeneGo Licenses MetaCore to Galapagos …
GeneGo said this week that drug discovery firm Galapagos will use its MetaCore pathway informatics system for research in several disease areas including osteoporosis, osteoarthritis, and rheumatoid arthritis.
Graham Dixon, senior vice president of drug discovery at Galapagos, said in a statement that the company has identified and validated several novel targets using its adenoviral technology platform in bone and joint diseases. “Applying MetaCore to this target set could allow us to gain valuable insights at the system level, thereby improving our understanding of the underlying disease biology and increasing our speed and success in finding new drugs against these targets.”
… and Integrates ABI's Tissue Gene-Expression Database Into MetaCore
GeneGo said this week that it has integrated Applied Biosystems’ tissue gene-expression database into its MetaCore data-mining platform.
Tatiana Nikolskaya, chief scientific officer and founder of GeneGo, said that the company integrated the database as a tissue-expression filter in the firm’s latest product release “to replace the publicly available, but less consistent, UniGene data.”
She added that the companies “look forward to collaborating on additional ways to leverage our complementary solutions.”
ABI created the database using its expression array system and human genome survey microarray. It comprises genome-wide gene-expression values from 31 normal tissues and a universal human reference RNA.
ABI said the combined product “facilitates” microarray experiments, such as comparing gene-expression changes in normal, diseased, or treated human tissues.
NOAA Licenses Rosetta Resolver for Marine Toxicogenomics
The National Oceanic and Atmospheric Administration has licensed the Rosetta Resolver system, Rosetta Biosoftware said this week.
NOAA’s Marine Biotoxins Program at the Center for Coastal Environmental Health and Biomolecular Research will use the gene expression analysis platform to study the toxicogenomic response of animal models and marine species to marine biotoxins, particularly algal toxins.
Resolver “will help us characterize the global transcriptional response of human cell lines and other models to marine neurotoxins," said Jimmy Ryan, an NOAA molecular biologist, in a statement.
The Marine Biotoxins Program focuses on harmful algal blooms, proliferations of microscopic algae that occur on all coasts of the US. These algal blooms produce neurotoxins that cause mass mortalities of marine life, including protected marine mammals, and can accumulate in shellfish.